Du Pen Stuart, Du Pen Anna, Hillyer Jon
Overlake Pain Medicine Clinic, Overlake Medical Center, Bellevue, Washington 98004, USA.
Pain Med. 2006 Jan-Feb;7(1):10-5. doi: 10.1111/j.1526-4637.2006.00083.x.
Hydromorphone is often administered intrathecally for the treatment of cancer and nonmalignant chronic intractable pain. It is frequently utilized in combination with other analgesics in a multidrug intrathecal infusion; however, very little data are available documenting efficacy or safety of intrathecal hydromorphone as a solo analgesic.
This study was conducted to examine pain and side effects in patients receiving intrathecal hydromorphone.
A retrospective review was conducted of all patients receiving intrathecal hydromorphone monotherapy in two large pain specialty practices in the Pacific Northwest. All data collected within 30 days of the patient's 3-month, 6-month, and 12-month anniversary of implant were analyzed.
Twenty-four patients with noncancer-related chronic pain were included in the study. Thirteen patients had eligible pain data at 1 month, 10 patients had pain data at 3 months and seven patients had pain data available at 12 months after initiation of intrathecal hydromorphone.
Average pain scores decreased significantly (P = 0.03). Side-effect and pain-interference scores remained essentially unchanged in this small sample of patients.
氢吗啡酮常用于鞘内注射以治疗癌症及非恶性慢性顽固性疼痛。它常与其他镇痛药联合用于多药鞘内输注；然而，关于鞘内注射氢吗啡酮作为单一镇痛药的疗效或安全性的资料非常少。
本研究旨在观察接受鞘内注射氢吗啡酮患者的疼痛情况及副作用。
对太平洋西北部两家大型疼痛专科诊所中所有接受鞘内注射氢吗啡酮单一疗法的患者进行回顾性研究。分析在患者植入后3个月、6个月和12个月纪念日的30天内收集的所有数据。
24例非癌症相关慢性疼痛患者纳入研究。13例患者在鞘内注射氢吗啡酮1个月时有符合要求的疼痛数据，10例患者在3个月时有疼痛数据，7例患者在开始鞘内注射氢吗啡酮12个月后有疼痛数据。
平均疼痛评分显著降低（P = 0.03）。在这个小样本患者中，副作用和疼痛干扰评分基本保持不变。
